← Human Trials & Peer-Reviewed Studies
Glucagon-like peptide-1 receptor agonists and retained gastric contents on endoscopy: a prospective observational study.
Plain-language guide to PMID 42618723 (2026): observational study of Glucagon.
Key Facts
- PMID
- 42618723
- Journal
- Canadian journal of anaesthesia = Journal canadien d'anesthesie
- Year
- 2026
- Study type
- Observational Study
- Authors
- Wilson PR et al. (6 authors)
- DOI
- 10.1007/s12630-026-03186-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glucagon in this observational study publication.
The primary aim of this study was to compare the incidence of RGC on upper endoscopy after appropriate preoperative fasting in patients taking GLP-1 RAs vs patients not taking GLP-1 RAs.
Who Took Part
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
The researchers conducted prospective observational study of 256 patients scheduled for elective endoscopy involving stomach visualization.
Control patients followed standard 8-hr fasting, while patients taking GLP-1 RAs were instructed to hold this medication 1 week prior and were limited to a preprocedural 24-hr clear liquid diet.
How the Study Was Run
The researchers measured RGCvia suctioning whenever possible and recorded subjective physician impressions.
Secondary outcomes included aspiration events, procedure abortion, and conversion to general anesthesia.
The researchers evaluated the differences between groups using two-sample t tests or Wilcoxon rank-sum test for continuous and ordinal variables and Chi square tests or Fisher's exact test for categorical variables.
The researchers analyzed potentially confounding variables via logistic regression.
What Was Measured
PubMed files the paper under topics including Glucagon-Like Peptide-1 Receptor Agonists, Fasting, Gastrointestinal Contents and Incidence.
Author keywords: anesthesia, esophagogastroduodenoscopy, retained gastric contents and upper endoscopy.
What This Means in Plain Language
This is an observational study of Glucagon.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Canadian journal of anaesthesia = Journal canadien d'anesthesie), a journal based in United States.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.